LB Pharmaceuticals director granted 20,000 stock options

LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock.

Accepted by SEC EDGAR 03/10/2026 - 04:19 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LB Pharmaceuticals director Robert A. Lenz received a grant of stock options for 20,000 shares of common stock. The options have an exercise price of $23.78 per share and expire on March 5, 2036. They vest in three equal annual installments on March 6, 2027, March 6, 2028, and March 6, 2029, contingent on continued service. Following this grant, he holds 20,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 20,000 shares

Grant/Award 1 txn

Insider Lenz Robert A.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	20,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 20,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did LB PHARMACEUTICALS INC (LBRX) director Robert Lenz report on this Form 4?

Director Robert A. Lenz reported receiving a grant of stock options for 20,000 shares of LB Pharmaceuticals common stock. These options represent compensation and give him the right to buy shares at a fixed exercise price in the future if vesting conditions are met.

How many LB PHARMACEUTICALS INC (LBRX) options were granted to Robert Lenz and at what price?

Robert A. Lenz was granted stock options covering 20,000 shares of LB Pharmaceuticals common stock. The options carry an exercise price of $23.78 per share, meaning he can purchase shares at that price once the options are vested and exercisable.

When do Robert Lenz’s LB PHARMACEUTICALS INC (LBRX) stock options vest?

The 20,000 stock options granted to Robert A. Lenz vest in three equal annual installments. Vesting dates are March 6, 2027, March 6, 2028, and March 6, 2029, provided he remains in continuous service through each of those dates.

Did Robert Lenz buy or sell any LB PHARMACEUTICALS INC (LBRX) shares in the market?

The Form 4 shows no market purchases or sales of LB Pharmaceuticals common stock by Robert A. Lenz. It reports only a compensation-related grant of stock options, with no open-market buy or sell transactions disclosed in this filing.

What is the expiration date of Robert Lenz’s LB PHARMACEUTICALS INC (LBRX) stock options?

The stock options granted to Robert A. Lenz expire on March 5, 2036. After that date, any unexercised options will lapse, and he will no longer have the right to purchase LB Pharmaceuticals common shares under this specific award.

How many LB PHARMACEUTICALS INC (LBRX) derivative securities does Robert Lenz hold after this Form 4?

Following this reported grant, Robert A. Lenz holds 20,000 derivative securities in the form of stock options. These options are held directly and give him the right to acquire an equal number of LB Pharmaceuticals common shares if exercised after vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lenz Robert A.

(Last) (First) (Middle)

C/O LB PHARMACEUTICALS INC

ONE PENNSYLVANIA PLAZA, SUITE 1025

(Street)

NEW YORK NY 10119

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LB PHARMACEUTICALS INC [ LBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.78	03/06/2026		A		20,000		(1)	03/05/2036	Common Stock	20,000	$0	20,000	D

Explanation of Responses:

1. The shares subject to the option award shall vest in three (3) equal annual installments on March 6, 2027, March 6, 2028 and March 6, 2029, subject to the Reporting Person's continuous service through each such date.

	/s/ Marc Panoff, Attorney-in-Fact	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.